FibroBiologics ups ATM offering to $7.5M; 71,830 shares sold to date

FibroBiologics, Inc.

Increased maximum aggregate offering price under ATM facility to $7.5 million.
71,830 shares of common stock sold to date under Sales Agreement with H.C. Wainwright & Co.
ATM offering uses existing S-3 shelf registration (effective Feb 10, 2025); prospectus supplement filed May 5, 2026.
Legal opinion and consent of Sichenzia Ross Ference Carmel LLP filed as exhibits.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.